CIK 0001620463
- Non-accelerated filer
- Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 453368487
- Phone
- +1 425-620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-20 | EDELMAN JOSEPH Director | Grant or award · Stock Option (Right to Buy) | +13,871 | 13,871 | ||
| 2022-05-20 | FLUKE JOHN M JR Director | Grant or award · Stock Option (Right to Buy) | +13,871 | 13,871 | ||
| 2022-05-20 | JOHNSON JAMES A Director | Grant or award · Stock Option (Right to Buy) | +13,871 | 13,871 | ||
| 2022-05-20 | Panzara Michael A. Director | Grant or award · Stock Option (Right to Buy) | +2,311 | 2,311 | ||
| 2022-05-20 | PERCEPTIVE ADVISORS LLC Director | Grant or award · Stock Option (Right to Buy) | +13,871 | 13,871 | ||
| 2022-05-18 | Worthington Mark General Counsel | Grant or award | +3,396 | $7.06 | $24K | 11,711 |
| 2022-05-18 | MOEBIUS HANS Chief Medical Officer | Grant or award | +1,699 | $7.06 | $12K | 32,955 |
| 2022-05-18 | MILESON GLENNA Chief Financial Officer | Grant or award | +1,721 | $7.06 | $12K | 101,781 |
| 2022-05-18 | Litton Mark James Chief Executive Officer | Grant or award | +757 | $7.06 | $5K | 116,515 |
| 2022-05-18 | CHURCH KEVIN Executive VP, Research | Grant or award | +243 | $7.06 | $2K | 47,809 |
| 2022-04-11 | MILESON GLENNA Chief Financial Officer | Exercise or conversion | +3,000 | $10.64 | $32K | 100,060 |
| 2022-04-11 | MILESON GLENNA Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) | −3,000 | 167,000 | ||
| 2022-03-31 | Romano Kelly A Director | Purchase | +8,000 | $13.11 | $105K | 8,315 |
| 2022-03-18 | Panzara Michael A. Director | Grant or award · Stock Option (Right to Buy) | +27,742 | 27,742 | ||
| 2022-02-18 | CHURCH KEVIN Executive VP, Research | Exercise or conversion | +3,152 | $1.19 | $4K | 47,566 |
| 2022-02-18 | CHURCH KEVIN Executive VP, Research | Exercise or conversion · Stock Option (Right to Buy) | −3,152 | 0 | ||
| 2022-01-27 | Litton Mark James Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2022-01-27 | PICKERING GRANT Director | Grant or award · Stock Option (Right to Buy) | +27,742 | 27,742 | ||
| 2022-01-18 | Lenington Rachel Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2022-01-18 | MILESON GLENNA Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 |
Page 14 of 18 · 349 trades